Business Context and Reporting Period
MediciNova, Inc. is a biopharmaceutical company developing small-molecule therapeutics for serious diseases with unmet medical needs. Its principal programs are MN-166 (ibudilast) for neurological disorders and substance dependence, MN-001 (tipelukast) for fibrotic diseases, MN-221 for acute asthma exacerbations, and MN-029 for solid tumors. This unaudited Form 10-Q covers the three months ended March 31, 2017, compared with the same period in 2016.
The company reported 34,540,543 common shares outstanding as of April 26, 2017. It has incurred significant losses since inception and is not yet generating product-sale revenue.
Key Financial Metrics
| Metric | Q1 2017 | Q1 2016 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No change |
| Research, development and patent expense | $0.9 million | $1.1 million | Down approximately $0.2 million |
| General and administrative expense | $2.1 million | $2.3 million | Down approximately $0.2 million |
| Total operating expenses | $3.0 million | $3.4 million | Down approximately $0.4 million |
| Operating loss | $3.0 million | $3.4 million | Improved approximately $0.4 million |
| Net loss | $3.0 million | $3.4 million | Improved approximately $0.4 million |
| Basic and diluted loss per share | $0.09 | $0.11 | Improved |
| Net cash used in operating activities | $2.5 million | $2.4 million | Use increased approximately $0.1 million |
| Cash and cash equivalents at period end | $21.6 million | $27.6 million | Down $6.0 million |
No meaningful profit margin can be calculated because the company reported no revenue. The filing does not report conventional interest-bearing debt. Total liabilities were $4.7 million, including $2.0 million of deferred tax liability and $1.7 million of long-term deferred revenue.
At March 31, 2017, total assets were $37.4 million, current assets were $22.3 million, current liabilities were $1.0 million, and working capital was approximately $21.3 million. The accumulated deficit was $333.3 million.
Material Changes Versus the Prior Comparable Period
- Research, development and patent expense declined approximately 16%, primarily because certain clinical studies were winding down.
- General and administrative expense declined approximately 8%, primarily because of lower performance-based stock compensation expense.
- Net loss improved from $3.4 million to $3.0 million, while loss per share improved from $0.11 to $0.09.
- Operating cash use increased modestly to $2.5 million from $2.4 million.
- Financing cash inflows fell sharply to $0.1 million from $8.0 million. Q1 2016 included proceeds from warrant and stock-option exercises; Q1 2017 financing proceeds primarily consisted of $65,025 from the employee stock purchase plan.
- The company sold 4,000 shares under its at-the-market facility for gross proceeds of $24,800 and incurred $23,668 of issuance costs.
- Stock-based compensation decreased to $1.2 million from $1.4 million and remained a significant non-cash operating expense.
Guidance, Outlook, Risks and Unusual Items
Management expects substantial net losses to continue for the next several years as development programs advance. The company expects research and development spending to increase during 2017 as programs progress, although the filing does not provide numerical expense or revenue guidance.
Management stated that available working capital was expected to fund operations at least through December 31, 2018, but cautioned that these resources may not be sufficient to conduct all planned research and development programs. Additional capital may be required depending on development decisions.
- Clinical, regulatory and commercialization risk remains substantial, including trial delays, patient enrollment challenges, safety concerns, inadequate efficacy and failure to obtain regulatory approvals.
- The company depends principally on the success of MN-166 and MN-001 and may need strategic partners to fund late-stage development and commercialization.
- Zhejiang Sunmy, the company’s Chinese joint venture for MN-221, requires a sublicense that had not been executed as of the filing date. The company has no future funding obligation but cannot assure that development in China will proceed.
- The company depends on third parties for clinical trials, manufacturing, marketing and distribution.
- Goodwill of $9.6 million and in-process research and development of $4.8 million are subject to impairment considerations.
- Outstanding warrants included 198,020 warrants exercisable at $6.06 per share expiring May 10, 2017, plus 869,047 warrants expiring May 9, 2018 at exercise prices of $3.15 and $3.38 per share.
- No material legal proceedings were reported, and management stated that there were no material changes to previously disclosed risk factors.
- Disclosure controls and procedures were assessed as effective at the reasonable assurance level, with no material change in internal control over financial reporting.
Important Facts for Investors to Verify
- Whether the $21.6 million cash balance and stated working capital runway remain adequate relative to planned clinical development spending.
- The timing, design, enrollment and results of MN-166 and MN-001 clinical programs, including externally funded and investigator-sponsored studies.
- Whether the company can secure strategic partnerships or additional financing without significant dilution.
- The status of the required MN-221 sublicense with Zhejiang Sunmy and the joint venture’s ability to advance the program in China.
- The potential effect of outstanding warrants, stock options and future equity sales on dilution and liquidity.
- Whether goodwill and in-process research and development remain recoverable as clinical and commercial prospects evolve.
- The company’s continued absence of product revenue and its ability to generate revenue from licensing, milestones or future product commercialization.